Hyperspectral imaging for early detection of Alzheimer's disease

Patent metadata

Field	Value
Publication number	US-12329457-B2
Application number	US-202318372439-A
Country	US
Kind code	B2
Filing date	Sep 25, 2023
Priority date	Dec 9, 2011
Publication date	Jun 17, 2025
Grant date	Jun 17, 2025

Abstract

Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.

First claim

What is claimed is:

1. A method for determining whether a subject has or is predisposed for developing a disorder associated with amyloidopathy or amyloidosis, the method comprising:
obtaining spectral data over a range of wavelengths from light reflected by an eye tissue of a subject by one or more processors from one or more detectors of a spectral imaging system; and
analyzing the spectral data at multiple light bands over the range of wavelengths to determine whether the spectral data is indicative of a formation of amyloid aggregates indicative of at least one of amyloidopathy or amyloidosis or a predisposition to at least one of amyloidopathy or amyloidosis in the subject.

2. The method of claim 1 , wherein the amyloid aggregates comprise soluble amyloid aggregates.

3. The method of claim 1 , wherein the amyloid aggregates are formed in one or more of a brain, eye, or central nervous system of the subject.

4. The method of claim 1 , wherein the range of wavelengths to obtain the spectral data are in a visible near infrared (VNIR) range.

5. The method of claim 1 , wherein the spectral data is hyperspectral data.

6. The method of claim 1 , further comprising obtaining the spectral data from a hyperspectral image of the eye tissue over the range of wavelengths.

7. The method of claim 1 , further comprising comparing the spectral data of the eye tissue to at least a first previous spectral data obtained from the eye tissue of the subject at an earlier point in time, wherein differences between the spectral data of the eye tissue and the first previous spectral data obtained from the eye tissue indicates the subject has one or more disorders resulting from at least one of amyloidopathy or amyloidosis or is predisposed for developing one or more disorders resulting from at least one of amyloidopathy or amyloidosis.

8. The method of claim 1 further comprising comparing the spectral data from the subject to a control spectral data and to a disorder reference spectral data to determine whether the spectral data comprises differences that are indicative of one or more disorders resulting from at least one of amyloidopathy or amyloidosis.

9. The method of claim 1 , further comprising obtaining the spectral data non-invasively and without administration of dyes for detection of amyloid aggregation.

10. The method of claim 1 , wherein the amyloidopathy or amyloidosis is indicative of cerebral amyloid angiopathy, familial amyloid polyneuropathy, Parkinson's disease, Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.

11. The method of claim 1 , wherein the amyloidopathy or amyloidosis is indicative of Alzheimer's disease.

12. A method for determining whether a treatment is effective comprising:
obtaining spectral data over a range of wavelengths from light reflected by an eye tissue of a subject by one or more processors from one or more detectors of a spectral imaging system; and
analyzing the spectral data at multiple light bands over the range of wavelengths to determine whether a treatment causes a decrease in formation of amyloid aggregates indicative of at least one of amyloidopathy or amyloidosis,
wherein a decrease in formation of amyloid aggregates is indicative of an effective treatment of a disorder associated with amyloidopathy or amyloidosis.

13. The method of claim 12 further comprising determining whether the spectral data is indicative of a change in amyloid aggregates.

14. The method of claim 13 , wherein the amyloid aggregates comprise soluble amyloid aggregates.

15. The method of claim 13 , wherein the amyloid aggregates are formed in one or more of a brain, eye, or central nervous system of the subject.

16. The method of claim 12 , wherein the disorder associated with amyloidopathy or amyloidosis is cerebral amyloid angiopathy, familial amyloid polyneuropathy, Parkinson's disease, Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.

17. The method of claim 12 further comprising comparing the spectral data of the eye tissue to at least a first previous spectral data obtained from the eye tissue of the subject at an earlier point in time to determine the decrease in formation of amyloid aggregates indicative of at least one of amyloidopathy or amyloidosis.

18. The method of claim 12 , wherein the disorder associated with amyloidopathy or amyloidosis is Alzheimer's disease.

19. A method for determining whether a test compound affects amyloid aggregation, comprising:
after contacting a cell comprising amyloid aggregates with a test compound, obtaining spectral data over a range of wavelengths from light reflected by the cell by one or more processors from one or more detectors of a spectral imaging system; and
analyzing the spectral data at multiple light bands over the range of wavelengths to determine whether the spectral data indicates that the test compound affects the amyloid aggregates in the cell.

20. The method of claim 19 , wherein the step of analyzing comprises comparing the spectral data to at least a first previous spectral data obtained from the cell at an earlier point in time to determine a change in the amyloid aggregates.

21. The method of claim 19 , wherein the method is an in vitro method.

22. The method of claim 19 , wherein the method is an in vivo method.

23. The method of claim 19 , wherein the cell is a retinal cell, brain cell, or central nervous system cell.

24. The method of claim 19 , wherein the amyloid aggregates comprise soluble amyloid aggregates.

25. The method of claim 19 , wherein the amyloid aggregates are associated with Alzheimer's disease.

26. The method of claim 19 , wherein the amyloid aggregates are associated with cerebral amyloid angiopathy, familial amyloid polyneuropathy, Parkinson's disease, Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.

27. A method for determining whether a subject has or is predisposed for developing a disorder associated with amyloidopathy or amyloidosis, the method comprising:
obtaining spectral data over a range of wavelengths from light reflected by an eye tissue of a subject by one or more processors from one or more detectors of a spectral imaging system; and
analyzing the spectral data at multiple light bands over the range of wavelengths to determine whether the spectral data is indicative of at least one of amyloidopathy or amyloidosis or a predisposition to at least one of amyloidopathy or amyloidosis in the subject by comparing the spectral data of the eye tissue to at least a first previous spectral data obtained from the eye tissue of the subject at an earlier point in time, wherein differences between the spectral data of the eye tissue and the first previous spectral data obtained from the eye tissue indicates the subject has one or more disorders resulting from at least one of amyloidopathy or amyloidosis or is predisposed for developing one or more disorders resulting from at least one of amyloidopathy or amyloidosis.

28. The method of claim 27 , wherein the one or more disorders is cerebral amyloid angiopathy, familial amyloid polyneuropathy, Parkinson's disease, Alzheimer's disease, Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.

29. A method for determining whether a subject has or is predisposed for developing a disorder

Assignees

• Univ Minnesota

Inventors

• Vince Robert
• More Swati Sudhakar

Classifications

• A61B5/4848

  Monitoring or testing the effects of treatment, e.g. of medication · CPC title

• G01N33/5038

  involving detection of metabolites per se · CPC title

• A61K38/063

  Glutathione · CPC title

• A61B3/14

  Arrangements specially adapted for eye photography · CPC title

• G01N21/25

  Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands · CPC title